Aizen hopes AI will help make mirror peptides a reality

Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, USA, has officially launched from stealth mode, introducing its drug discovery platform, DaX.

Developed in collaboration with Caltech researcher David Van Valen, the platform uses computational tools to design so-called mirror peptides, a novel class of therapeutics.

Composed entirely of D-amino acids, these serve as mirror images of naturally occurring proteins and peptides, which are typically composed of L-amino acids. This unique structure offers enhanced stability, reduced immunogenicity, and strong target-binding affinity.